Maruho Co., Ltd.
http://www.maruho.co.jp/english/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Maruho Co., Ltd.
Deal Watch: BI Acquires Nerio For Novel Immune Checkpoint Inhibitor
Featuring deals involving Novartis/Dren, Palvella/Pieris, Eyenovia/Senju, Addex/Johnson & Johnson, Agilent/BioVectra, Meitheal/Nabriva, plus tech transfer agreements and deals in brief.
Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.
Are Korean Biopharma Alliances Recovering After Gloomy Year?
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice